Latanoprost-induced stabilization of central visual function in patients with primary open-angle glaucoma

Area of Science:

• Ophthalmology
• Glaucoma Research
• Visual Neuroscience

Background:

• Contrast sensitivity (CS) is a key measure of visual function.
• Previous treatments like beta-blockers and trabeculoplasty have shown to improve CS in primary open-angle glaucoma (POAG).
• Ocular hypotensive agents, including latanoprost, may offer visual benefits beyond IOP reduction.

Purpose of the Study:

• To prospectively compare the effects of latanoprost and timolol maleate in Gelrite on contrast sensitivity (CS) in POAG patients.
• To evaluate if latanoprost offers superior visual function benefits compared to timolol.
• To assess changes in CS at various spatial frequencies.

Main Methods:

• A single-masked, randomized, crossover study involving 20 POAG patients on stable monotherapy.
• Patients were treated with latanoprost 0.005% or timolol maleate 0.5% in Gelrite for 3 months each, with a crossover period.
• Intraocular pressure (IOP), blood pressure, heart rate, and CS were assessed regularly; visual-field sensitivity was also evaluated.

Main Results:

• Latanoprost treatment led to improved CS at 3 cycles/degree (cpd) after switching from timolol (P=0.03).
• Timolol treatment resulted in decreased CS at 3 cpd (P=0.04) and 18 cpd (P=0.03) after switching from latanoprost.
• These CS changes occurred independently of significant changes in IOP between treatments.

Conclusions:

• Latanoprost demonstrates a significant ability to improve or maintain central visual function, specifically CS, in POAG patients.
• Timolol maleate in Gelrite may lead to a decline in CS at certain spatial frequencies.
• Latanoprost appears to be a more favorable option for preserving visual function in POAG compared to timolol maleate in Gelrite.